Peritoneal Mesothelioma

Overview

Symptoms

  • Digestive problems

  • Weight loss

  • Occasionally a palpable abdominal mass

Diagnosis

  • Abdomen/Pelvis CT Scan with Contrast – Provides detailed views of the peritoneum and extent of disease.

  • Abdomen FDG-PET Scan – Helps assess spread and distinguish cancerous from benign tissue.

  • Abdomen MRI – Sometimes used to evaluate disease burden in preparation for surgery.

  • Laparoscopic Biopsy – Requires general anesthesia, but widely considered the preferred approach for diagnosis because it yields larger, better-quality tissue and lets the surgeon simultaneously asses disease extent and whether complete cytoreduction look feasible.

  • Image-Guided Percutaneous Needle Biopsy – Minimally invasive and often done under local anesthesia; good for accessible areas of peritoneal thickening, but less reliable when disease is patchy or small-volume.

  • Laparotomy – The most invasive procedure that is used when laparoscopy isn’t feasible/adequate or when more extensive surgical assessment is needed.

Staging

  • LS-0 – No visible tumor

  • LS-1 – Tumor is small (up to approximately half a centimeter)

  • LS-2 – Tumor is medium (approximately half a centimeter to 5 centimeters)

  • LS-3 – Tumor is large (bigger than 5 centimeters) or many tumors have merged together

Treatments

Chemotherapy/Immunotherapy

  • Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Pemetrexed (Alimta) Plus Pembrolizumab (Keytruda) – FDA-approved in 2024, this chemo-immunotherapy combination adds an immunotherapy boost to the familiar chemotherapy backbone and is appealing for epithelioid pleural mesothelioma or for patients where the treatment team wants chemotherapy’s direct tumor activity alongside immune activation.

  • Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Pemetrexed (Alimta) Plus Bevacizumab (Avastin) – Can sometimes extend survival in eligible patients when added to the traditional platinum doublet

  • Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Gemcitabine (Gemzar) – Sometimes offered when a patient can’t take Pemetrexed due to contraindications, intolerance or cost considerations.

  • Vinorelbine (Navelbine) – Typically offered second-line once a patient progresses on platinum doublet chemotherapy, but may be offered first-line to pleural mesothelioma patients who can’t tolerate or aren’t good candidates for platinum doublet chemotherapy or immunotherapy.

  • Pemetrexed (Alimta) – Sometimes offered second-line as maintenance monotherapy to continue disease control or first-line for selected elderly patients or those unfit for platinum doublet chemotherapy and immunotherapy.

  • Hyperthermic Intraperitoneal Chemotherapy (HIPEC) – A cornerstone of treatment for eligible patients, HIPEC is almost always done in conjunction with cytoreductive surgery (CRS). It delivers heated chemotherapy (typically Cisplatin-based) directly into the abdominal cavity to kill microscopic disease left behind after surgery.

  • Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) – An early-stage, experimental procedure that is not combined with surgical removal of the main tumor. PITAC delivers chemotherapy as a pressurized aerosol mist into the pleural cavity via a special device, which spreads it evenly across the chest surfaces and helps it penetrate tumor tissue.

Surgery

  • CC-2 – Residual nodules between 2.5 millimeters and 2.5 centimeters

  • CC-3 – Residual nodules larger than 2.5 centimeters or extensive unresectable disease

Radiation

Clinical Trials

A note about this information

phone icon CALL FOR HELP NOW 888.891.2200